Mounjaro, Zepbound Lower Death Risk for People With Serious Heart Conditions
Why this matters: health reporting relevant to everyday decisions and well-being.
GLP-1 drugs containing tirzepatide significantly reduce cardiovascular risks in people with serious heart conditions. Indranil MUKHERJEE / AFP via Getty Images GLP-1 weight loss medications containing tirzepatide (Mounjaro, Zepbound) can reduce heart-related health risks for people with serious heart conditions, according to new research. Experts say the heart health benefits are produced by the drugs’ ability to help people lose weight and control blood sugar levels. People using these medications should also maintain a healthy lifestyle, including daily exercise and a balanced diet, to maintain overall health. Weight loss medications containing the active ingredient tirzepatide significantly reduce cardiovascular risks in people with serious heart conditions, according to new research. The results of two studies indicate that GLP-1 drugs containing tirzepatide (i.e., Mounjaro, Zepbound) may lower heart-related risks for people undergoing percutaneous coronary intervention (PCI) and those with obesity undergoing transcatheter aortic valve replacement (TAVR). The researchers presented their findings at the SCAI 2026 Scientific Sessions & CAIC-ACCI Summit in Montreal from April 23–25. The two studies have not yet been published in a peer-reviewed scientific journal. Tirzepatide medications are usually prescribed to help treat type 2 diabetes. According to a news release for the two studies, tirzepatide’s ability to manage blood sugar levels and promote weight loss delivers “meaningful cardiovascular benefits.” While prior research has established these benefits, their impacts on patients undergoing interventional heart procedures have not yet been extensively evaluated. Notably, the researchers found a 62% lower risk of death among participants receiving tirzepatide who underwent a PCI procedure. “GLP-1 agonists represent an important evolution in cardiometabolic care,” said SCAI President Srihari Naidu, MD, an interventional cardiologist, in the news rel